Stefano A Pileri

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda
    Lynnette K Tumwine
    Department of Pathology, School of Biomedical Sciences, College of Health Sciences, Makerere University, P, O, Box 7072, Kampala, Uganda
    Infect Agent Cancer 5:12. 2010
  2. ncbi Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
    Ellen C Obermann
    Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany
    BMC Cancer 5:162. 2005
  3. ncbi The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis
    Stefano A Pileri
    Lymphoma Study Group, Institute of Haematology and Clinical Oncology, Bologna University, Italy
    Haematologica 90:293. 2005
  4. ncbi Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challenges
    Stefano A Pileri
    Institute of Hematology and Clinical Oncology, Bologna University
    Haematologica 90:148. 2005
  5. ncbi Histopathology of B-cell chronic lymphocytic leukemia
    Stefano A Pileri
    Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Hematol Oncol Clin North Am 18:807-26, viii. 2004
  6. ncbi Pathobiology of primary mediastinal B-cell lymphoma
    Stefano A Pileri
    Institute of Haematology Seragnoli, Bologna University, Policinico S Orsola, Via Massarenti 9, 40138, Bologna, Italy
    Leuk Lymphoma 44:S21-6. 2003
  7. ncbi Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
    S A Pileri
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Leukemia 21:340-50. 2007
  8. ncbi Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
  9. ncbi Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    , Hematology and Hematopathology Units, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
  10. ncbi Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008

Detail Information

Publications66

  1. ncbi EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda
    Lynnette K Tumwine
    Department of Pathology, School of Biomedical Sciences, College of Health Sciences, Makerere University, P, O, Box 7072, Kampala, Uganda
    Infect Agent Cancer 5:12. 2010
    ..However, the possible linkages of HHV8 and EBV to the condition of impaired immunity present in AIDS are still not yet very clearly understood...
  2. ncbi Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
    Ellen C Obermann
    Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany
    BMC Cancer 5:162. 2005
    ....
  3. ncbi The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis
    Stefano A Pileri
    Lymphoma Study Group, Institute of Haematology and Clinical Oncology, Bologna University, Italy
    Haematologica 90:293. 2005
  4. ncbi Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challenges
    Stefano A Pileri
    Institute of Hematology and Clinical Oncology, Bologna University
    Haematologica 90:148. 2005
  5. ncbi Histopathology of B-cell chronic lymphocytic leukemia
    Stefano A Pileri
    Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Hematol Oncol Clin North Am 18:807-26, viii. 2004
    ..The relevance of the examination of trephines and surgical specimens is outlined with special reference to the identification of risk factors in individual patients...
  6. ncbi Pathobiology of primary mediastinal B-cell lymphoma
    Stefano A Pileri
    Institute of Haematology Seragnoli, Bologna University, Policinico S Orsola, Via Massarenti 9, 40138, Bologna, Italy
    Leuk Lymphoma 44:S21-6. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgV(H) gene crippling mutations...
  7. ncbi Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
    S A Pileri
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Leukemia 21:340-50. 2007
    ....
  8. ncbi Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
    ..This study investigated the role of immunohistochemical discrimination between GCB and ABC&NC-DLBCL subtypes in identifying those high-risk patients who may benefit from a more aggressive first-line therapeutic approach...
  9. ncbi Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    , Hematology and Hematopathology Units, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
    ..The latter represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials...
  10. ncbi Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008
    ..Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned...
  11. ncbi Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
    Enrico Derenzini
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:1824-9. 2009
    ..R-MACOP-B regimen followed by involved-field radiation on bulky presentation is safe and very effective in the treatment of young patients with low-risk DLBCL...
  12. ncbi CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified
    Anna Gazzola
    Department of Haematology and Oncological Sciences L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Pathol 64:83-7. 2011
    ..CDKN1B/p27, a critical regulator of cell cycle and proliferation, has been suggested to be involved in T cell lymphomagenesis. This study aimed to evaluate the possible occurrence of CDKN1B/p27 aberrations in PTCL/NOS...
  13. ncbi Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins
    Stefano A Pileri
    Istituto di Ematologia e Oncologia Medica, L e A Seràgnoli Unità Cliniche e di Anatomia Patologica, Universita di Bologna, Bologna, Italy
    Am J Pathol 162:243-53. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations...
  14. ncbi Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Res 67:10703-10. 2007
    ..Our study provides new relevant information on AILT biology and new candidates for possible therapeutic targets such as PDGFRA (platelet-derived growth factor alpha) and VEGF...
  15. ncbi BCL10 down-regulation in peripheral T-cell lymphomas
    Maura Rossi
    Molecular Pathology Laboratory, Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Hum Pathol 43:2266-73. 2012
    ..In conclusion, BCL10 was commonly down-regulated in peripheral T cell lymphomas, suggest the T-cell receptor signaling cascade for future characterization...
  16. ncbi Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples
    Claudio Agostinelli
    Departments of Haematology and Clinical Oncology L and A Seràgnoli, Pathology and Haematopathology Unit, St Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Appl Immunohistochem Mol Morphol 18:561-72. 2010
    ..We describe the newly generated DAK-PAX5 monoclonal antibody raised against a fixation-resistant epitope of the human PAX5/BSAP molecule...
  17. ncbi Prognostic markers in peripheral T-cell lymphoma
    Pier Paolo Piccaluga
    Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Curr Hematol Malig Rep 5:222-8. 2010
    ..The validation process for several models, including clinical-pathological and molecular models, is now ongoing...
  18. ncbi Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays
    Pier Luigi Zinzani
    Pathologic Anatomy and Lymphoma Unit, Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Haematologica 90:341-7. 2005
    ..Patients with diffuse large B-cell lymphoma (DLBCL) could benefit from integration of well-established bioclinical prognostic factors with new tools - such as micro-arrays - exploring aberrant gene and/or protein expression...
  19. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    , S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  20. ncbi Pathobiology of hodgkin lymphoma
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, 40126 Bologna, Italy
    Adv Hematol 2011:920898. 2011
    ..Treatments adjusted to the pathobiological characteristics of the tumor in at-risk patients have been proposed and are on the way to being applied...
  21. ncbi Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? Revising Karl Lennert's personal archive
    Claudio Agostinelli
    Haematopathology Section, Department of Haematology and Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Italy
    Histopathology 59:679-91. 2011
    ..To revise 25 cases selected from Karl Lennert's personal archive (21) and Bologna and Frankfurt Registries (four) because of cytological similarities...
  22. ncbi Peripheral T-cell lymphoma classification: the matter of cellular derivation
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Expert Rev Hematol 4:415-25. 2011
    ....
  23. ncbi Lymphoma classification: the quiet after the storm
    Stefano A Pileri
    Department of Haematology and Oncological Sciences L and A Seragnoli, Bologna University School of Medicine, Bologna, Italy
    Semin Diagn Pathol 28:113-23. 2011
    ..The present review aims to analyse future perspectives after the fourth edition of the WHO Classification released in 2008...
  24. ncbi Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes
    Pier Paolo Piccaluga
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Hematopathology Unit, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Blood 117:3596-608. 2011
    ..In conclusion, our study provided substantial insights on the pathobiology of BLs, by offering novel evidences that may be relevant for its classification and possibly future treatment...
  25. ncbi Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma
    Stefano Ascani
    Unit of Hematopathology, , Bologna University, Bologna, Italy
    J Clin Oncol 22:953-4. 2004
  26. ncbi Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody
    Claudio Agostinelli
    Section of Haematopathology, Department of Haematology and Oncological Sciences Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Histopathology 61:33-46. 2012
    ..We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2)...
  27. ncbi Biology and treatment of follicular lymphoma
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Unit, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Expert Rev Hematol 2:533-47. 2009
    ..Novel approaches, including stem cell transplantation, monoclonal antibodies and innovative agents, should be then considered for improving long-term results...
  28. ncbi Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature
    Valentina Tabanelli
    Department of Hematology and Oncological Sciences L and A Seràgnoli, Hematopathology Section, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Med Case Reports 5:218. 2011
    ..abstract:..
  29. ncbi Pathobiology of ALK-negative anaplastic large cell lymphoma
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Pediatr Rep 3:e5. 2011
    ..The main histological findings are illustrated as well as the phenotypic, molecular and clinical characteristics. Finally, the biological rationale for possible innovative targeted therapies is presented...
  30. ncbi Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome
    Stefano Ascani
    Unit of Hematopathology, , Bologna University, St. Orsola Hospital, Bologna, Italy
    Haematologica 89:EIM07. 2004
  31. ncbi Primary cutaneous lymphomas: a reprisal
    Alessandro Pileri
    Department of Internal Medicine, Geriatrics, and Nephrology, Division of Dermatology, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:214-33. 2011
    ..Our aim is to evaluate the commonest types of PCL analysing the clinical characteristics, histology, phenotype, molecular biology, prognosis and therapy...
  32. ncbi Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 117:823-34. 2007
    ..These results, which might be extended to other more rare PTCL categories, provide insight into tumor pathogenesis and clinical management of PTCL/U...
  33. ncbi Pathobiology of Epstein-Barr virus-driven peripheral T-cell lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Section, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Semin Diagn Pathol 28:234-44. 2011
    ..For example, the nuclear factor-KB pathway and platelet-derived growth factor receptor inhibition may represent 2 options to be tested in clinical trials...
  34. ncbi Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases
    Cristina Campidelli
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, Unit of Hematopathology, Bologna University School of Medicine, Bologna, Italy
    Hum Pathol 38:787-92. 2007
    ..To the best of our knowledge, the simultaneous occurrence of PTCL unspecified and B-cell small lymphocytic lymphoma is an exceptional event; the possible pathogenetic correlations between the 2 neoplasms are discussed...
  35. ncbi Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Serànoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:469-72. 2006
    ....
  36. ncbi Follicular lymphoma: still Six characters in search of an author?
    Pier Paolo Piccaluga
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Leuk Lymphoma 52:1655-67. 2011
    ..This review was inspired by the reappraisal of Professor Lennert's personal archive that represents a unique legacy for the entire scientific community...
  37. ncbi Molecular profiling of aggressive lymphomas
    Maura Rossi
    Molecular Pathology Laboratory, Haematopathology Unit, Department of Haematology and Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Adv Hematol 2012:464680. 2012
    ..In this paper, the authors based on their own experience and the most updated literature review, the main concept on molecular profiling of aggressive lymphomas...
  38. ncbi Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified
    Pier Paolo Piccaluga
    Institute for Cancer Genetics, Columbia University, New York, NY, USA
    Lancet Oncol 6:440. 2005
  39. ncbi New molecular insights into peripheral T cell lymphomas
    Stefano A Pileri
    Hematopathology Section, Department of Hematology and Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 122:3448-55. 2012
    ....
  40. ncbi Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 87:1258-64. 2002
    ....
  41. ncbi Primary bone lymphoma: experience with 52 patients
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica L and A Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 88:280-5. 2003
    ..A retrospective analysis was performed to assess the efficacy of various treatments of non-Hodgkin's primary bone lymphomas (PBL)...
  42. ncbi Granulocytic sarcoma of main biliary ducts
    Stefano Ascani
    Unit of Haematopathology, , Bologna University, St. Orsola Hospital, Bologna, Italy
    Br J Haematol 121:534. 2003
  43. ncbi Myeloid sarcoma: extramedullary manifestation of myeloid disorders
    Cristina Campidelli
    Unit of Haematopathology, Institute of Haematology and Oncological Sciences L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, 40138 Bologna, Italy
    Am J Clin Pathol 132:426-37. 2009
    ....
  44. ncbi Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms
    Teresa Marafioti
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom
    Am J Pathol 162:861-71. 2003
    ....
  45. ncbi Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells?
    Cristiana Bellan
    Institute of Pathologic Anatomy and Histopathology, University of Siena, Italy
    Diagn Mol Pathol 11:2-8. 2002
    ....
  46. ncbi Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology
    Teresa Marafioti
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom
    Blood 102:2868-76. 2003
    ..Studies in experimental animals should help to elucidate the role of these cells in the immune response...
  47. ncbi Construction and validation of a bone marrow tissue microarray
    Annette Zimpfer
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    J Clin Pathol 60:57-61. 2007
    ..50 cases of the TMA were directly compared with the corresponding full tissue section to validate the results...
  48. ncbi Rare expression of T-cell markers in classical Hodgkin's lymphoma
    Alexandar Tzankov
    Institute of Pathology, Medical University of Innsbruck, Innsbruck, Austria
    Mod Pathol 18:1542-9. 2005
    ..Therefore, T-cell antigen expression on Hodgkin's and Reed-Sternberg cells is aberrant in the majority of cases and only infrequently classical Hodgkin's lymphomas are of T-cell origin...
  49. ncbi A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy
    Marcella Visentini
    Leuk Lymphoma 47:1421-3. 2006
  50. ncbi Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase
    Ellen C Obermann
    Institute of Pathology, University of Regensburg, Regensburg, Germany
    J Clin Pathol 60:794-7. 2007
    ..Chronic lymphocytic leukaemia (CLL) is a frequent non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Assessment of cell cycle phase kinetics might be important for prediction of clinical behaviour and prognosis...
  51. ncbi Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells
    Paola Secchiero
    Department of Morphology and Embryology, Human Anatomy Section, University of Ferrara, Italy
    Am J Pathol 167:1599-607. 2005
    ..Taken together, our data indicate that COX-2 overexpression likely represents an additional mechanism of resistance to apoptosis in B-CLL and that pharmacological suppression of COX-2 might enhance chemotherapy-mediated apoptosis...
  52. ncbi Expression of CD52 in peripheral T-cell lymphoma
    Pier Paolo Piccaluga
    Haematologica 92:566-7. 2007
    ....
  53. ncbi The NFATc1 transcription factor is widely expressed in white cells and translocates from the cytoplasm to the nucleus in a subset of human lymphomas
    Teresa Marafioti
    Leukaemia Research Fund Immunodiagnostics Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Br J Haematol 128:333-42. 2005
    ..It would be of interest to correlate this feature with patterns of gene expression and also with prognosis, since it may identify a subset of human lymphoma that is distinct in its molecular and clinical features...
  54. ncbi Novel markers of normal and neoplastic human plasmacytoid dendritic cells
    Teresa Marafioti
    Leukaemia Research Fund Immunodiagnostics Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, UK
    Blood 111:3778-92. 2008
    ....
  55. ncbi Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
    Alexandar Tzankov
    Department of Pathology, University Hospital Basel, Schoenbeinstr 40, CH 4031 Basel, Switzerland
    Haematologica 93:193-200. 2008
    ..The tumor microenvironment is important for the behavior of cancer. We assessed the distribution and biological significance of FOXP3(+) regulatory T-cells (Treg) in lymphomas...
  56. ncbi ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
    Kerry J Savage
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
    Blood 111:5496-504. 2008
    ..Although the prognosis of ALK(-) ALCL appears to be better than that for PTCL-NOS, it is still unsatisfactory and better therapies are needed. Primary cutaneous ALCL is associated with an indolent course...
  57. ncbi B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray
    Lynnette K Tumwine
    Department of Pathology, Makerere University Medical School, PO Box 7072, Kampala, Uganda
    Hum Pathol 39:817-23. 2008
    ..The availability of TMAs and immunohistochemistry has enabled us to precisely categorize tumors that have so far been diagnosed in Uganda as "high-grade/aggressive" lymphomas on the basis of cell morphology alone...
  58. ncbi Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy
    Leuk Res 28:1165-9. 2004
    ....
  59. ncbi Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease
    Teresa Marafioti
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Haematologica 89:957-64. 2004
    ..In this paper, we have evaluated the usefulness of the pan-leukocyte marker LSP1 and the transcription factor PU.1 for resolving such diagnostic problems...
  60. ncbi Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling
    Charles H Lawrie
    Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, UK
    Int J Cancer 118:3161-6. 2006
    ..271). We suggest that this technique could provide a powerful tool for identifying novel carbohydrates in other cancers...
  61. ncbi Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas
    Cristiana Bellan
    Department of Human Pathology and Oncology, University of Siena, Italy
    Blood 106:1031-6. 2005
    ..The different types of C-MYC translocation reported in BL may also be related to the different stages of B-cell maturation...
  62. ncbi Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia
    Davide Rossi
    Hematology Unit, Dept. of Medical Sciences and IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
    Haematologica 89:154-64. 2004
    ..Finally, the frequency of GSTP1 aberrant methylation in diffuse large B-cell lymphoma prompts studies aimed at verifying the prognostic impact of this epigenetic lesion in these lymphomas...
  63. ncbi Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease
    Teresa Marafioti
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom
    Blood 103:188-93. 2004
    ..Furthermore, the clear difference in expression of signaling proteins between the 2 major subtypes of Hodgkin disease may be of diagnostic value...
  64. ncbi High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia
    Philip Th Went
    Institute for Pathology, University of Basel, Basel, Switzerland
    Am J Surg Pathol 29:474-8. 2005
    ..44/TRAP expression analysis in confirming the diagnosis of HCL. However, combined positivity for these markers is highly sensitive but not absolutely specific for HCL...
  65. ncbi Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting
    Maurilio Ponzoni
    Unit of Lymphoma Malignancies, Pathology and Oncology Units, Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
    J Clin Oncol 25:3168-73. 2007
    ..Finally, a provisional practical diagnostic approach to hemophagocytosis-associated patients and a proposal for the most useful criteria in the settings of differential diagnosis are included...
  66. ncbi Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia
    Pier Paolo Piccaluga
    Cancer Genet Cytogenet 151:85-6. 2004